Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Rx Spending Growth Projected To Stay Modest; Will Political Debate Change?

Executive Summary

The latest update by the US Centers for Medicare & Medicaid Services to national health care spending forecasts continues to put prescription drugs in line with – or even slightly below – overall growth rates. Of course, that likely won’t change the political attention to the issue in 2022.

You may also be interested in...

Vaccines For Uninsured Adults Initiative Proposed In Biden’s Federal Budget For 2023

Biden budget proposal also addresses consolidating all Medicare coverage for vaccines under Part B, providing Medicare and Medicaid 'explicit' authority to cover vaccines approved under emergency use authorizations without cost sharing, and increasing 340B spending on program oversight.

Senate Democrats Running Out Of Time On Drug Pricing Reform

Is less ambitious drug pricing reform better than nothing? Senate Finance Committee Chair Wyden still pushing for a version of the most aggressive policy, direct government price negotiation.  

Copay Coupons, Lower Utilization Reduced Out-Of-Pocket Spending On Retail Drugs In 2020

Overall drug spending rose 3% to $348bn in 2020, according to the latest US National Health Expenditures report. COVID-19 lowered drug utilization and spending, but not as much as it impacted health care services.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts